Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMKZYV)

Drug Name

Namitecan Drug Info

Synonyms

ST-1968; ST-1976; ST-2649; ST-2724; ST-3280; ST-3833; ST-4167; ST-4215; ST-5548; Peptide-camptothecin conjugates (cancer); Topoisomerase I inhibiting camptothecin analog (cancer), Sigma-Tau; Topoisomerase I inhibitor (cancer), Sigma-Tau; Peptide-camptothecin conjugates (cancer), Sigma-Tau

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 10950142
CAS Number: CAS 372105-27-6
TTD Drug ID: DMMKZYV

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting DNA topoisomerase I (TOP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[3]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[3]
B-Lactams	DMR8YD6	Bacterial infection	1A00-1C4Z	Approved	[4]
Belotecan hydrocholoride	DM3SRJZ	Small-cell lung cancer	2C25.Y	Approved	[5]
Topetecan	DMAE6LK	Small-cell lung cancer	2C25.Y	Approved	[6]
Karenitecin	DMCRGY4	Lung cancer	2C25.0	Phase 3	[7]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Exatecan	DMCA7FN	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
Edotecarin	DM3ZL7D	Gastric adenocarcinoma	2B72	Phase 3	[10]
Rubitecan	DMDWU1S	Human immunodeficiency virus infection	1C62	Phase 3	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01748019) ST1968 Intravenous (Weekly) in Solid Tumors. U.S. National Institutes of Health.
2	Namitecan: a hydrophilic camptothecin with a promising preclinical profile. Curr Med Chem. 2012;19(21):3488-501.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
5	Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
6	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7	Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
8	Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
9	Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
10	Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
11	Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.